FrancophonIA/ELRC3.0 huggingface dataset:
English: As safety and efficacy of repetition of the treatment to treat fibrosarcoma recurrence have not been investigated, repetition of the treatment should be considered by the veterinarian taking into account the benefit-risk balance.
Maltese: Peres li s-sigurtà u l-effikaċja tar-repetizzjoni tal-kura kontra rikorrenza tal-fibrosarcoma ma ġewx investigati, ir-ripetizzjoni tal-kura għandha tiġi studjata mill-veterinarju u l-bilanċ benefiċċju/riskju għandu jiġi kkunsidrat.
English: Lyophilisate and solvent for suspension for injection
Maltese: GĦAMLA FARMAĊEWTIKA Lijofiliżat u solvent għal suspensjoni għal injezzjoni
English: A moderate local reaction (pain on palpation, swelling, scratching) occurred very commonly in safety studies.
Maltese: Kien hemm b'mod komuni reazzjoni lokali moderata (wġigħ malli tintmiss, nefħa, ħakk) fi studji dwar is-sigurtà.
English: Laboratoire Porte des Alpes Rue de l'Aviation
Maltese: Rue de ħ'Aviation
English: After reconstitution of the lyophilisate with the solvent, shake gently and administer five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar.
Maltese: Wara r-rikostituzzjoni tal-lijofiliżat mas-solvent, amministra ħames injezzjonijiet (kull waħda bejn wieħed u ieħor 0.2 ml) madwar il-post fejn tneħħa t-tumur: injezzjoni f'kull rokna u injezzjoni fiċ ċentru ta' kwadru ta' 5 cm x 5 cm iċċentrat fin-nofs tal-farrett tal-operazzjoni.
English: Moreover feline IL-2 has been shown to have very low biological activity on human leukocytes compared to human IL-2.
Maltese: IL-2 ġie muri li għandu attività bijoloġika baxxa ħafna fuq il-lewkoċiti umani meta mqabbla ma' IL-2
English: Cardboard box containing 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.
Maltese: Kaxxa tal-kartun li fiha 6 kunjetti ta' doża waħda ta' lijofiliżat u 6 kunjetti ta' ml ta' solvent.
English: After two years of study follow-up, Oncept IL-2 treated cats showed a longer median time to relapse (above 730 days) compared to control cats (287 days).
Maltese: Wara perjodu insegwitu ta' sentejn millistudju, dawk il-qtates li ħadu l-kura bl-Oncept IL-2 wrew żmien medju iżjed fit-tul biex jirkadu ('il fuq minn 730 jum) meta mqabbla ma' qtates ta' kontroll (287 jum).
English: Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis).
Maltese: (dijametru ta' 2-5 cm) mingħajr metastasi jew effetti fuq il-lymph nodes, biex jitnaqqas ir-riskju li terġa toħroġ il-marda u żżid iż-żmien li tirkadi (rikorrenza lokali jew metastasi).
English: Store in the original package in order to protect from light.
Maltese: Ħallih fil-pakkett oriġinali biex tipproteġi mid-dawl.
English: Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.
Maltese: Tħallatx ma' ebda prodott mediċinali veterinarju ieħor, ħlief mas-solvent provdut għall-użu ma dan ilprodott mediċinali veterinarju .
English: Type I glass vial with a butyl elastomer closure, sealed with an aluminium cap. Cardboard box of 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.
Maltese: Tħallatx ma' ebda prodott mediċinali veterinarju ieħor, ħlief mas-solvent provdut għall-użu ma' dan ilprodott mediċinali veterinarju .
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 September 2016 EMA/275240/2014
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 ta' Settembru 2016
English: Passion flower EMA/275240/2014
Maltese: EMA/275240/2014
English: Passion flower
Maltese: Fjura tal-Passjoni
English: What are the risks associated with passion flower medicines?
Maltese: X'inhuma r-riskji assoċjati mal-mediċini li fihom il-fjura tal-passjoni?
English: Passion flower medicines should only be used in adults and adolescents over the age of 12 years.
Maltese: Il-mediċini li fihom il-fjura tal-passjoni għandhom jintużaw biss f'adulti u adolexxenti li għandhom 'il fuq minn 12-il sena.
English: Other information about passion flower medicines
Maltese: Aktar informazzjoni dwar il-mediċini li fihom il-fjura tal-passjoni
English: Further information on the HMPC assessment of passion flower medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Maltese: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Further information on the risks associated with these passion flower medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Maltese: Aktar informazzjoni dwar il-valutazzjoni tal-HMPC tal-mediċini li fihom il-fjura tal-passjoni, inklużi ddettalji tal-konklużjonijiet tal-Kumitat, tinsab taħt it-tab ‘Id-dokumenti kollha' (All Documents') is-sit elettroniku tal-Aġenzija:
English: In its assessment, the HMPC also considered published clinical studies of passion flower medicines.
Maltese: Fil-valutazzjoni tiegħu, l-HMPC ikkunsidra studji kliniċi ppubblikati ta' mediċini li fihom il-fjura talpassjoni.
English: Passion flower is the common name for the above-ground parts of the plant Passiflora incarnata L. The HMPC conclusions only cover passion flower preparations which are obtained by comminuting (reducing into tiny pieces) or powdering the dried above-ground parts or as dry and liquid extracts.
Maltese: Il-konklużjonijiet tal-HMPC ikopru biss il-preparazzjonijiet tal-fjura tal-passjoni li jinkisbu billi jindaħnu (f'biċċiet iżgħar) il-partijiet 'il fuq mill-art imnixxfa jew bħala estrazzjonijiet niexfa u likwidi. Lestrazzjonijiet jinkisbu billi tpoġġi l-materjali tal-pjanta f'solvent (bħall-etanol), biex jinħallu lkomponenti u jiffurmaw estratt likwidu.
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Maltese: Dan ifisser li, għalkemm m'hemmx biżżejjed evidenza minn provi kliniċi, leffikaċja ta' dawn il-mediċini tal-ħxejjex hija plawżibbli u hemm evidenza li ilhom jintużaw b'mod sigur b'dan il-mod mill-inqas 30 sena (inkluż mill-inqas 15-il sena fl-UE).
English: To obtain a dry extract the solvent is then evaporated.
Maltese: Is-solvent imbagħad jiġi evaporat biex jinkiseb estratt niexef.
English: Herbal medicines containing these passion flower preparations are usually available as herbal teas to be drunk or as solid or liquid forms to be taken by mouth.
Maltese: mediċina, għandu jiġi kkonsultat tabib jew prattikant tal-kura tas-saħħa kwalifikat.
English: Further information of Targretin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This overview was last updated in 04-2018.
Maltese: Din il-ħarsa ġenerali ġiet aġġornata l-aħħar fi: 04-2018.
English: Targretin received a marketing authorisation valid throughout the EU on 29 March 2001.
Maltese: Targretin irċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE fid-29 ta' Marzu 2001.
English: Targretin is available as capsules (75 mg).
Maltese: Targretin jiġi bħala kapsuli (75 mg).
English: Other information about Targretin
Maltese: Informazzjoni oħra dwar Targretin
English: The response rates according to the 5 skin scores were 36% and 27%, respectively.
Maltese: Ir-rati tar-rispons skont il-5 punteġġi tal-ġilda kienu 36 % u 27 %, rispettivament.
English: Sixty-one patients were treated at the starting dose of 300 mg/m2/day.
Maltese: Wieħed u sittin pazjent ġew ikkurati bid-doża tal-bidu ta' 300 mg/m2/jum.
English: The most common side effects with Targretin (which may affect more than 1 patient in 10) are leucopenia (reduced white cell count), hypothyroidism (underactive thyroid gland), hyperlipaemia (high levels of fats in the blood), hypercholesterolaemia (high blood cholesterol), exfoliative dermatitis (skin peeling), pruritus (itching), rash, pain, headache and weakness.
Maltese: L-effetti sekondarji l-aktar komuni b'Targretin (li jistgħu jaffettwaw aktar minn 1 minn kull 10) huma lewkopenija (għadd imnaqqas taċ-ċelloli bojod), ipotirojdiżmu (glandola tat-tirojde mhux attiva biżżejjed), iperlipemija (livelli għoljin ta' xaħam fid-demm), iperkolesterolemija (kolesterol għoli fiddemm), dermatite esfoljattiva (tqaxxir tal-ġilda), pruritu (ħakk), raxx, uġigħ, uġigħ ta' ras u dgħufija.
English: Targretin must not be used in women who are pregnant or breast-feeding, or women who could become pregnant and who are not using effective contraception; patients who have had pancreatitis (inflammation of the pancreas); patients with uncontrolled hypercholesterolaemia (high blood cholesterol), hypertriglyceridaemia (high blood triglycerides [fat]) or thyroid disease; patients with hypervitaminosis A (high levels of vitamin A); patients with liver disease; patients with an ongoing body infection.
Maltese: Targretin m'għandux jintuża f'nisa li huma tqal jew qed ireddgħu, jew nisa li jistgħu joħorġu tqal u li mhumiex jużaw kontraċettiv effettiv; pazjenti li kellhom pankreatite (infjammazzjoni tal-frixa); pazjenti b'iperkolesterolemija mhux ikkontrollata (kolesterol għoli fid-demm), ipertrigliċeridemija (trigliċeridi [xaħam] għoljin [għoli] fid-demm) jew marda tat-tirojde; pazjenti b'ipervitaminożi A (livelli għoljin tal-vitamina A); pazjenti b'mard fil-fwied; pazjenti b'infezzjoni fil-ġisem li tkun għadha għaddejja.
English: What are the risks associated with Targretin?
Maltese: X'inhuma r-riskji assoċjati ma' Targretin?
English: As for all medicines, data on the use of Targretin are continuously monitored.
Maltese: Bħal l-mediċini kollha, id-data dwar l-użu ta' Targretin hija ssorveljata kontinwament.
English: Targretin is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous Tcell lymphoma (CTCL).
Maltese: Targretin huwa mediċina tal-kanċer li tintuża għall-kura ta' sinjali li jidhru fuq il-ġilda ta' linfoma taċċelloli T taħt il-ġilda (CTCL, cutaneous T-cell lymphoma).
English: Targretin was not compared with another medicine.
Maltese: Targretin ma tqabbilx ma' mediċina oħra.
English: How is Targretin used?
Maltese: Targretin?
English: The active substance in Targretin, bexarotene, belongs to the group of retinoids, substances that are derived from vitamin A. The exact way bexarotene works in CTCL is not known.
Maltese: Is-sustanza attiva f'Targretin, il-bexarotene, tappartjeni għall-grupp ta' retinojdi, sustanzi li huma derivati mill-vitamina A.
English: For the full list of side effects reported with Targretin, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji rrappurtati bi Targretin, ara l-fuljett ta' tagħrif.
English: The dose of Targretin is based on the patient's body surface area in square metres (m2).
Maltese: Id-doża ta' Targretin hija bbażata fuq l-erja tas-superfiċje talġisem tal-pazjent f'metri kwadri (m2).
English: The effectiveness of Targretin has been examined in two studies involving a total of 193 patients with CTCL who received at least two previous treatments.
Maltese: L-effikaċja ta' Targretin ġiet eżaminata f'żewġ studji li involvew total ta' 193 pazjent b'CTCL li rċivew tal-inqas żewġ kuri preċedenti.
English: The European Medicines Agency decided that Targretin's benefits are greater than its risks for the treatment of the skin manifestations of advanced-stage CTCL patients refractory to at least one treatment.
Maltese: L-Aġenzija Ewropea għall-Mediċini iddeċidiet li l-benefiċċji ta' Targretin huma akbar mir-riskji tiegħu għall-kura tal-manifestazzjonijiet tal-ġilda ta' pazjenti b'CTCL ta' stadju avvanzat refrattorja għal talinqas kura waħda.
English: CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin.
Maltese: CTCL hija tip rari ta' linfoma (kanċer tattessut linfatiku) fejn xi ċelloli bojod tad-demm (ċelloli T) jikbru fil-ġilda.
English: grading of improvement, as well as by a score of 5 clinical signs (area of skin affected, redness, raised areas, scale-like skin and colour).
Maltese: Dan tkejjel mill-klassifikazzjoni tat-titjib mit-tabib, kif ukoll minn punteġġ ta' 5 sinjali kliniċi (parti tal-ġilda affettwata, ħmura, partijiet imqabbżin, ġilda qisha bil-qoxra u l-kulur).
English: The recommended starting dose is 300 mg/m2/day, taken as a single dose once a day with a meal.
Maltese: Id-doża tal-bidu rakkomandata hija 300 mg/m2/jum, li tittieħed bħala doża waħda darba kuljum mal-ikel.
English: The Agency recommended that Targretin be given marketing authorisation.
Maltese: Aktar informazzjoni fuq Targretin tinstab fis-sit elettroniku tal-Aġenzija:
English: EMA/672677/2013 EMEA/H/C/002783
Maltese: EMEA/H/C/002783
English: The full EPAR for Levetiracetam Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: L-EPAR sħiħ għal Levetiracetam Hospira jinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Hospira on the 08 January 2014.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Levetiracetam Hospira fl-08 ta' Jannar 2014.
English: Levetiracetam Hospira is a ‘generic medicine'.
Maltese: Levetiracetam Hospira huwa ‘mediċina ġenerika'.
English: In patients aged between four and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day.
Maltese: F'pazjenti bejn erba' snin u 17-il sena li jiżnu inqas minn 50 kg, id-doża talbidu hija ta' 10 mg għal kull kilogramm tal-piż tal-ġisem darbtejn kuljum, li tista' tiżdied sa 30mg/kg darbtejn kuljum.
English: The active substance in Levetiracetam Hospira, levetiracetam, is an anti-epileptic medicine.
Maltese: Is-sustanza attiva f'Levetiracetam Hospira, il-levetiracetam, hija mediċina antiepilettika.
English: The exact way in which levetiracetam works is still unclear but it seems to interfere with a protein called synaptic vesicle protein 2A, which is found in the spaces between nerves and is involved in the release of chemical messengers from nerve cells.
Maltese: Il-mod preċiż kif levetiracetam jaħdem għadu mhux ċar iżda jidher li jinterferixxi ma' proteina msejħa proteina sinaptika vexxili 2A, li tinstab flispazji ta' bejn in-nervituri, u hija involuta fir-rilaxx ta' messaġġiera kimiċi miċ-ċelloli tan-nervituri.
English: • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Maltese: • aċċessjonijiet toniċi-kloniċi ġeneralizzati primarji (attakki severi, inkluż it-telf tal-koxjenza) f'pazjenti minn 12-il sena 'l fuq li jbatu bl-epilessija ġeneralizzata idjopatika (it-tip ta' epilessija li maħsuba li għandha kawża ġenetika).
English: Other information about Levetiracetam Hospira
Maltese: Informazzjoni oħra dwar Levetiracetam Hospira
English: This is a summary of the European public assessment report (EPAR) for Levetiracetam Hospira.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Levetiracetam Hospira.
English: This means that Levetiracetam Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
Maltese: Dan ifisser li Levetiracetam Hospira huwa simili għall‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) magħrufa bħala Keppra.
English: Levetiracetam Hospira levetiracetam
Maltese: Kif jintuża Levetiracetam Hospira?
English: • myoclonic seizures (short, shock-like jerks of a muscle or a group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy;
Maltese: • aċċessjonijiet mijokloniċi (movimenti spażmodiċi u qosra donnhom xokkijiet ta' muskolu jew ta' grupp ta' muskoli) f'pazjenti minn tnax-il sena 'l fuq li jbatu bl-epilessija mijoklonika ġuvenili;
English: Why is Levetiracetam Hospira approved?
Maltese: Għaliex ġie approvat Levetiracetam Hospira?
English: When Levetiracetam Hospira is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing 50 kg or more is 500 mg twice a day.
Maltese: Meta Levetiracetam Hospira jiżdied ma' kura antiepilettika oħra, id-doża tal-bidu f'pazjenti 'l fuq minn 12-il sena li jiżnu 50 kg jew aktar hija ta' 500 mg darbtejn kuljum.
English: No additional studies were needed as Levetiracetam Hospira is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Keppra.
Maltese: Ma kienx hemm il-ħtieġa għal studji addizzjonali peress li Levetiracetam Hospira huwa mediċina ġenerika li tingħata permezz ta' infużjoni u fiha l-istess sustanza attiva bħall-mediċina ta' referenza, Keppra.
English: This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one side of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear.
Maltese: Din hija tip ta' epilessija fejn attività elettrika eċċessiva f'naħa waħda tal-moħħ tikkawża sintomi bħal movimenti spażmodiċi għall-għarrieda fuq naħa waħda tal-ġisem, smigħ, xamm, jew viżta mhux ċari, titrix, jew sens ta' biża' f'daqqa.
English: When Levetiracetam Hospira is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Maltese: Meta Levetiracetam Hospira jintuża waħdu, id-doża tal-bidu hija ta' 250 mg darbtejn kuljum, u tiżdied ġimagħtejn wara għal 500 mg darbtejn kuljum.
English: Levetiracetam Hospira is an anti-epileptic medicine that contains the active substance levetiracetam.
Maltese: Levetiracetam Hospira huwa mediċina antiepilettika li fiha s-sustanza attiva levetiracetam.
English: Levetiracetam Hospira can only be obtained with a prescription and is available as a concentrate (100 mg/ml) that is made up into a solution for infusion (drip) into a vein.
Maltese: Levetiracetam Hospira jista' jinkiseb biss b'riċetta ta' tabib u jiġi bħala konċentrat (100 mg/ml) li jiġi magħmul f'soluzzjoni għall-infużjoni (dripp) ġo vina.
English: Because Levetiracetam Hospira is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Levetiracetam Hospira huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: The company provided data from the published literature on levetiracetam.
Maltese: Il-kumpanija pprovdiet dejta mil-letteratura ppubblikata dwar levetiracetam.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Levetiracetam Hospira has been shown to have comparable quality and to be bioequivalent to Keppra.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) tal-Aġenzija kkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Levetiracetam Hospira wera li għandu kwalità komparabbli u li huwa bijoekwivalenti għal Keppra.
English: A risk management plan has been developed to ensure that Levetiracetam Hospira is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Levetiracetam Hospira jintuża bl-aktar mod sigur possibbli.
English: What are the benefits and risks of Levetiracetam Hospira?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Levetiracetam Hospira?
English: This helps Levetiracetam Hospira to stabilise electrical activity in the brain and prevent seizures.
Maltese: Dan jgħin biex Levetiracetam Hospira jistabbilizza l-attività elettrika fil-moħħ u jipprevjeni l-aċċessjonijiet.
English: Therefore, the CHMP's view was that, as for Keppra, the benefit outweighs the identified risk.
Maltese: Għaldaqstant, il-fehma tas-CHMP kienet li, bħal fil-każ ta' Keppra, ilbenefiċċju huwa akbar mir-riskju identifikat.
English: How has Levetiracetam Hospira been studied?
Maltese: Kif jaħdem Levetiracetam Hospira?
English: The dose can be further increased at two-week intervals according to the patient's response, to a maximum dose of 1,500 mg twice a day.
Maltese: Id-doża tista' tkompli tiżdied f'intervalli ta' ġimagħtejn skont ir-rispons tal-pazjent, għal doża massima ta' 1,500 mg darbtejn kuljum.
English: The Committee recommended that Levetiracetam Hospira be approved for use in the EU.
Maltese: Il-Kumitat irrakkomanda li Levetiracetam Hospira ikun approvat għall-użu fl-UE.
English: Further information on Myalepta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The active substance in Myalepta, metreleptin, is similar to leptin.
Maltese: Is-sustanza attiva f'Myalepta, il-metreleptin, hija simili għal leptin.
English: Other information about Myalepta
Maltese: Informazzjoni oħra dwar Myalepta
English: • adults and children above the age of 12 years with partial (localised) lipodystrophy (including Barraquer-Simons syndrome), when standard treatments have failed.
Maltese: • adulti u tfal ta' ‘l fuq minn 12-il sena b'lipodistrofija parzjali (lokalizzata) (inkluż sindrome ta' Barraquer-Simons) meta kuri standard ma jkunux ħadmu.
English: • adults and children above the age of 2 years with generalised (throughout the body) lipodystrophy (Berardinelli-Seip syndrome and Lawrence syndrome);
Maltese: • adulti u tfal ta' ‘l fuq minn sentejn b'lipodistrofija ġeneralizzata (mal-ġisem kollu) (sindrome ta' Berardinelli-Seip u sindrome ta' Lawrence);
English: Insulin resistance was also improved: blood levels of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, fell from 8.6% to 6.4% in patients with generalised lipodystrophy, and from 8.8% to 8.0% in patients with partial lipodystrophy.
Maltese: Ir-reżistenza għall-insulina tjiebet ukoll: il-livelli fid-demm ta' sustanza msejħa emoglobina glikosilata (HbA1c), li tagħti indikazzjoni ta' kemm qed jiġi kkontrollat tajjeb il-glukożju fid-demm, naqsu minn 8.6 % għal 6.4 % f'pazjenti b'lipodistrofija ġeneralizzata, u minn 8.8 % għal 8.0 % f'pazjenti b'lipodistrofija parzjali.
English: Myalepta contains the active substance metreleptin.
Maltese: Myalepta fih is-sustanza attiva metreleptin.
English: After 12 months of treatment, blood levels of fats (triglycerides) decreased from around 15 mmol/l to around 5 mmol/l in patients with generalised disease, and from around 16 mmol/l to around 6 mmol/l in patients with partial disease.
Maltese: Wara 12-il xahar ta' kura, il-livelli ta' xaħam fid-demm (trigliċeridi) naqsu minn madwar 15 mmol/l għal madwar 5 mmol/l f'pazjenti b'marda ġeneralizzata, u minn madwar 16 mmol/l għal madwar 6 mmol/l f'pazjenti b'marda parzjali.
English: What are the risks associated with Myalepta?
Maltese: X'inhuma r-riskji assoċjati ma' Myalepta?
English: Myalepta has been shown to be effective at lowering blood fat levels in 2 main studies involving a total of 107 adults and children with generalised or partial lipodystrophy.
Maltese: Myalepta ntwera li huwa effettiv biex ibaxxi l-livelli ta' xaħam fid-demm f'2 studji ewlenin li involvew total ta' 107 adult u tfal b'lipodistrofija ġeneralizzata jew parzjali.
English: What information is still awaited for Myalepta?
Maltese: Liema informazzjoni għadha mistennija għal Myalepta?